Cancer Genomics and Epigenomics

Organizer(s): Andrew P. Feinberg, Greg J. Hannon and Rolf Ohlsson

Supported by the Director's Fund

For important information on the coronavirus, please click here

Summary of Meeting:

In the “post-genome” era, in which the human DNA sequence is available, as are those of many animal models, cancer genetics is being transformed both by the access to this sequence and by the technology that the genome project facilitated. It is now clear that many genetic changes occur in tumors, including mutations and copy number changes, as well as an even larger number of epigenetic alterations, such as altered DNA methylation, chromatin modification, and loss of genomic imprinting. High-throughput genomic and epigenomic approaches are now available, but are also being developed to assess the scope of these genomic/epigenomic changes. There is also a deeper evolution of our understanding that the genome and epigenome may be intrinsically disrupted in tumors, for example by palindrome formation and whole-band methylation. These advances raise several major questions, including: • Which genetic and epigenetic changes play a causal role in tumor initiation and progression? • What is the genetic and epigenetic basis of cancer predisposition? • Is there large scale disruption of the cancer genome and epigenome and how does this arise? • And how can we exploit advances in cancer genomics and epigenomics? • What are the cutting edge technologies that will advance the sensitivity of detection of subpopulations such as cancer stem cells? This symposium will explore the technological developments, large scale alterations, and gene-specific changes emerging in the genome-wide approach to cancer, as well as the implications of these discoveries for cancer prevention and therapy.

Scholarship Deadline: October 19 2007

Discounted Abstract Deadline: October 19 2007

Abstract Deadline: November 19 2007

Discounted Registration Deadline: December 19 2007

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Affymetrix, Inc.

We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA132471-01

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations